Preclinical Appraisal of Hematinic Potential of Mandura Bhasma for Treating Anemia

Khobragade, Deepak S. and Potbhare, Mrunali S. and Pimpale, Awdhut and Wankhede, Sagar B. and Tempe, Chandrashekhar R. (2021) Preclinical Appraisal of Hematinic Potential of Mandura Bhasma for Treating Anemia. Journal of Pharmaceutical Research International, 33 (30B). pp. 207-214. ISSN 2456-9119

[thumbnail of 2486-Article Text-4151-1-10-20221006.pdf] Text
2486-Article Text-4151-1-10-20221006.pdf - Published Version
Download (603kB)

Abstract

Aims: To evaluate hematinic potential of mandura bhasma.

Study Design: Experimental study.

Place and Duration of Study: Institute of Pharmaceutical Education and Research, Wardha, Maharashtra, India. 6 Months.

Methodology: The anti-anaemic potential of Mandura bhasma in Wistar rats was investigated. Anaemia was induced in rats with phenyl hydrazine hydrochloride at a dose of 10 mg kg-1 body weight by oral administration. Anaemia was treated with mandura bhasma administered in three different doses based on body weight.

Results: In vivo investigation showed that though the dose of 6mg kg-1 body weight of mandura bhasm produced only a minimal antianaemic (hematinic) effect, oral daily dose of 11 mg kg-1 body weight and 22mg kg-1 body weight a produced a significant (P < 0.05) antianaemic effect when compared to standard drug ferrous sulphate indicating dose dependent activity.

Conclusions: The results indicate that Mandura Bhasm have very potential dose dependant hematinic activity and can be a safe and effective drug for treating anemia.

Item Type: Article
Subjects: Scholar Eprints > Medical Science
Depositing User: Managing Editor
Date Deposited: 03 Feb 2023 07:07
Last Modified: 21 Sep 2024 04:54
URI: http://repository.stmscientificarchives.com/id/eprint/609

Actions (login required)

View Item
View Item